- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02646059
The Effective Ways of Recruiting Lapsed Blood Donors: a Stratified Randomized Pilot Study
July 30, 2017 updated by: OUYANG Jian, Guangzhou Blood Center
Blood donor recruitment is an important issue in every country, since the blood supply pressure become more and more intense.
Donor retention is even more important, because it is easier to recruit an old customers than a new one.
Therefore, figuring the most effective ways of recruiting lapsed blood donors and understanding the reasons of not donating blood again is critical and vital for the development of blood donation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1188
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510095
- Guangzhou Blood Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Donated blood at least once between 2009 to 2013, and the blood test result is qualified.
Exclusion Criteria:
- Having donated again before intervened.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
No intervention will be giving to this group.
|
|
Experimental: Text group
Text messages containing reminds of blood donation information would be sent to donors in this group.
|
Text messages would be sent via the messaging platform of Guangzhou Blood Center.
The feedback of sending status (received, failed to receive, or unknown) would be marked on every number.
Four to six months follow-up, blood donation rate would be checked.
|
Experimental: Telephone group
Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
|
Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked.
Four to six months follow-up, blood donation rate would be checked.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood donation rate
Time Frame: four to six months
|
Number of blood donors donate blood again divided by the number of participants in every group after intervened.
|
four to six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reasons of not donating again
Time Frame: 1 months
|
The reasons of not donating again in the telephone group.
|
1 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
January 4, 2016
First Submitted That Met QC Criteria
January 4, 2016
First Posted (Estimate)
January 5, 2016
Study Record Updates
Last Update Posted (Actual)
August 1, 2017
Last Update Submitted That Met QC Criteria
July 30, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- GuangzhouBC1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Donor
-
Haemonetics CorporationCompletedTransmission, Blood, Recipient/DonorUnited States
-
Haemonetics CorporationCompletedTransmission, Blood, Recipient/DonorUnited States
-
Haemonetics CorporationCompletedTransmission, Blood, Recipient/DonorUnited States
-
Haukeland University HospitalCompletedAutologous Blood Transfusion | Physical Performance | Donor SafetyNorway
-
Oslo University HospitalUniversity of Oslo; South-Eastern Norway Regional Health AuthorityCompletedRenal Transplant Donor of Left Kidney | Renal Transplant Donor of Right KidneyNorway
-
University of Maryland, BaltimoreCompletedRobotic Surgery | Renal Transplant Donor of Left Kidney | Donor Nephrectomy | Single-portUnited States
-
Guangzhou Blood CenterCompleted
-
Guangzhou Blood CenterCompleted
-
Radboud University Medical CenterMerck Sharp & Dohme LLCCompletedSurgery | Neuromuscular Block | Renal Transplant Donor of Left Kidney | Renal Transplant Donor of Right KidneyNetherlands
Clinical Trials on Text message
-
University of California, San FranciscoUniversity of WashingtonCompleted
-
University of WashingtonUniversity of Illinois at Chicago; Kenya Medical Research InstituteCompletedHIV Infections | Acquired Immunodeficiency Syndrome | Circumcision, Male | Patient Compliance | Cellular PhoneKenya
-
Texas Tech University Health Sciences CenterTexas Tech UniversityCompletedBreast Cancer FemaleUnited States
-
University of WashingtonUniversity of California, San Francisco; Kenya Medical Research InstituteCompletedHIV Infections | Acquired Immunodeficiency SyndromeKenya
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Wake Forest University Health SciencesCompleted
-
New York City Health and Hospitals CorporationWithdrawn
-
University of PittsburghCompleted
-
Jonsson Comprehensive Cancer CentereHealth International, INC.RecruitingObesity | Malignant NeoplasmUnited States
-
Columbia UniversityPfizerCompletedVaccinationUnited States